All News

Emma Murter, PharmD, MPH, and Madison N. Irwin, PharmD, BCPS, discuss the potential role of low-dose naltrexone in managing chronic pain in palliative care, highlighting its anti-inflammatory properties, limited adverse effects, and current evidence gaps—particularly in comparison to traditional opioids and adjuvant analgesics.

While vaccine research and approvals continue to break new ground, use and faith in them are faltering.

The process provides an opportunity for personal and professional growth.

PharmStart empowers pharmacy technicians to pursue their education with tuition-free prerequisites, addressing barriers to entering pharmacy school.

In approximately 84% of cases, the mask was able to detect if patients had chronic kidney disease (CKD).

The study found that only 38% of nations have risk-based pneumococcal vaccine policies.

Specialty pharmacy experts and key opinion leaders gathered at Asembia’s AXS25 Summit and discussed critical insights in interviews with Pharmacy Times®.

New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.

The new at-home test aims to increase comfort and screening timeliness through a more accessible method.

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.

Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication.

A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.

These findings demonstrate an association that is independent of the disease’s genetic predisposition.

Plozasiran shows promise in reducing cholesterol and triglyceride levels in patients with mixed hyperlipidemia and other harmful conditions, addressing significant cardiovascular risks.

Student pharmacists can work toward a better future for patients, themselves, and the profession.

The fixed-dose combination yielded a 49% greater reduction in low density lipoprotein cholesterol (LDL-C) compared with placebo.

With the FDA approval, avutometinib/defactinib is now the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).

New research reveals that B vitamins and choline may slow glaucoma progression, offering hope for innovative treatments beyond traditional methods.

The Ensuring Community Access to Pharmacist Services (ECAPS) Act would enhance Medicare coverage for pharmacist services and ensure seniors can access essential care in underserved areas.

These results build off prior studies which demonstrated effectiveness of Bergen 4-day treatment (B4DT) in patients with panic disorders.

Pharmacists can educate patients on nonpharmacologic strategies that help improve survival outcomes.

The agent demonstrated promising tolerability and manageable safety.

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

Necrotizing enterocolitis (NEC) is a life-threatening illness that is characterized by the inflammation of the intestinal lining, which can lead to intestinal perforation.

Dracey Poore explores the future of biosimilars, emphasizing the need for increased adoption.